anti-CD19 UCAR-T cells

BIOLOGICAL2 trials

Sponsors

Xinqiao Hospital of Chongqing, Chongqing Precision Biotech Co., Ltd

Conditions

B-cell Acute Lymphoblastic LeukemiaB-cell LymphomaDermatomyositisDermatomyositis, Juvenile

Early Phase 1

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

Xinqiao Hospital of ChongqingB-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma

Start: 2020-04-01End: 2022-04-01Target: 30Updated: 2020-02-11

Phase 1

Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)

RecruitingNCT06686524

Chongqing Precision Biotech Co., LtdDermatomyositis, Dermatomyositis, Juvenile

Start: 2024-11-11End: 2027-11-10Target: 18Updated: 2024-11-13